Skip to content
Back to search

Germany – Pharmaceutical products – Abschluss einer nicht-exklusiven Rabattvereinbarung nach § 130a Abs. 8 SGB V zum Wirkstoff Allergenextrakt aus ausschließlich Wiesenlieschgraspollen, ATC V01AA02 für die Zeit 01.10.2026 - 31.10.2027

DAK-GesundheitGermanyPublished on Aug 17, 2026
293 days left

Description

Section 130a, paragraph 8, SGB V allows health insurance funds and pharmaceutical companies to conclude framework discount contracts for medicines to be dispensed at the expense of the statutory health insurance funds. In view of the relevant legal provisions for the award of public contracts, a regular process of substance-related, formal tendering procedures according to the regulations of Part 4 of the GWB is carried out by DAK-Gesundheit. For medicines to be specified by the bidder in more detail in Appendix 2 to the contract, for the aforementioned active substance Allergenextract from exclusively meadow fescue pollen, ATC V01AA02, DAK-Gesundheit intends to conclude discount contracts for medicines with as many interested pharmaceutical companies as possible until new drug discount contracts come into force. A discount contract under the approval model for the aforementioned active substance comes into force for the first time on 01.10.2026 and expires on 31.10.2027. It automatically expires with the entry into force of the exclusive contract, regardless.

CPV codes

Pharmaceutical products

Documents & submission

AI summary
Sign in for an AI summary

Contains data from Tenders Electronic Daily (TED), © European Union, ted.europa.eu — CC BY 4.0.

Related tenders